Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 24 results.
User Information
Export Records
  1. 1.   Design, Synthesis and Biological Investigation of 2-Anilino Triazolopyrimidines as Tubulin Polymerization Inhibitors with Anticancer Activities
  2. Romagnoli, Romeo; Oliva, Paola; Prencipe, Filippo; Manfredini, Stefano; Budassi, Federica; Brancale, Andrea; Ferla, Salvatore; Hamel,Ernest; Corallo, Diana; Aveic, Sanja; Manfreda, Lorenzo; Mariotto, Elena; Bortolozzi, Roberta; Viola, Giampietro
  3. Pharmaceuticals (Basel, Switzerland). 2022, Aug 21; 15(8):
  1. 2.   The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity
  2. Xiang, Weiguo; Quadery, Tasdique M; Hamel,Ernest; Luckett-Chastain, Lerin R; Ihnat, Michael A; Mooberry, Susan L; Gangjee, Aleem
  3. Bioorganic & medicinal chemistry. 2021, Jan 1; 29: 115887.
  1. 3.   Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors [1]
  2. Andreani, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Varoli, L.; Lannigan, D.; Smith, J.; Scudiero, D.; Kondapaka, S.; Shoemaker, R. H.
  3. European Journal of Medicinal Chemistry. 2011, Sep; 46(9): 4311-4323.
  1. 4.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 5.   CB694, a novel antimitotic with antitumor activities
  2. Weiderhold, K. N.; Randall-Hiubek, D. A.; Polin, L. A.; Hamel, E.; Mooberry, S. L
  3. International Journal of Cancer. 2006, FEB 15; 118(4): 1032-1040.
  1. 6.   The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma
  2. Herranz, M.; Martin-Caballero, J.; Fraga, M. F.; Ruiz-Cabello, J.; Flores, J. M.; Desco, M.; Marquez, V.; Esteller, M.
  3. Blood. 2006, FEB 1; 107(3): 1174-1177.
  1. 7.   Antitumor activity and distribution of pyrroloiminoquinones in the sponge genus Zyzzya
  2. Dijoux, M. G.; Schnabel, P. C.; Hallock, Y. F.; Boswell, J. L.; Johnson, T. R.; Wilson, J. A.; Irel, C. M.; van Soest, R.; Boyd, M. R.; Barrows, L. R.; Cardellina, J. H.
  3. Bioorganic & Medicinal Chemistry. 2005, NOV 1; 13(21): 6035-6044.
  1. 8.   In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
  2. Hollingshead, M.; Alley, M.; Burger, A. M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H. H.; Sausville, E. A.
  3. Cancer Chemotherapy and Pharmacology. 2005, AUG; 56(2): 115-125.
  1. 9.   In vivo hydrodynamic delivery of cDNA encoding IL-2: Rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells
  2. Ortaldo, J. R.; Winkler-Pickett, R. T.; Bere, E. W.; Watanabe, M.; Murphy, W. J.; Wiltrout, R. H.
  3. Journal of Immunology. 2005, JUL 15; 175(2): 693-699.
  1. 10.   Azidothymidine inhibits NF-kappa B and induces Epstein-Barr virus gene expression in Burkitt lymphoma
  2. Kurokawa, M.; Ghosh, S. K.; Ramos, J. C.; Mian, A. M.; Toomey, N. L.; Cabral, L.; Whitby, D.; Barber, G. N.; Dittmer, D. P.; Harrington, W. J.
  3. Blood. 2005, JUL 1; 106(1): 235-240.
  1. 11.   Elucidation of thioredoxin as a molecular target for antitumor quinols
  2. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. G.
  3. Cancer Research. 2005, MAY 1; 65(9): 3911-3919.
  1. 12.   Tumor cell IFN-gamma responsiveness mediates the generation of tumor-specific immunologic reactivity and overall antitumor activity of IL-18 in mice bearing neuroblastoma tumors
  2. Hixon, J.; Stauffer, J. K.; Khan, T.; Salcedo, R.; Lincoln, E.; Back, T. C.; Jonak, Z.; Dar, M.; Wigginton, J. M.
  3. Journal of Immunotherapy. 2005, NOV-DEC; 28(6): 627-627.
  1. 13.   Proteasome inhibition upregulates the cell surface expression of receptors for IFN-gamma and TNF-alpha on murine neuroblastoma cells and enhances the proapoptotic and overall antitumor activity of systemic cytokine therapy in murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Lockett, S.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunotherapy. 2005, NOV-DEC; 28(6): 640-640.
  1. 14.   NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Hollingshead, M. G.
  3. Anticancer Research. 2005, MAY-JUN; 25(3B): 1865-1869.
  1. 15.   Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology
  2. Marquez, V. E.; Barchi, J. J.; Kelley, J. A.; Rao, K. V. R.; Agbaria, R.; Ben-Kasus, T.; Cheng, J. C.; Yoo, C. B.; Jones, P. A.
  3. Nucleosides Nucleotides & Nucleic Acids. 2005 24(5-7, Sp. Iss.): 305-318.
  1. 16.   Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy
  2. Marquez, V. E.; Kelley, J. A.; Agbaria, R.; Ben-Kasus, T.; Cheng, J. C.; Yoo, C. B.; Jones, P. A.
  3. Therapeutic Oligonucleotides: Transcriptional and Translational Strategies for Silencing Gene Expression. 2005; 1058 : 246-254.
  1. 17.   IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8(+) T cells
  2. Salcedo, R.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Hixon, J. A.; Hahn, C.; Shafer-Weaver, K.; Malyguine, A.; Kastelein, R.; Wigginton, J. M.
  3. Journal of Immunology. 2004, DEC 15; 173(12): 7170-7182.
  1. 18.   Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice
  2. Kim, H. W.; Park, I. K.; Cho, C. S.; Lee, K. H.; Beck, G. R.; Colburn, N. H.; Cho, M. H.
  3. Cancer Research. 2004, NOV 1; 64(21): 7971-7976.
  1. 19.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
  1. 20.   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models
  2. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D.
  3. Breast Cancer Research and Treatment. 2004, SEP; 87(1): 97-107.
  1. 21.   Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity
  2. Jansen, A. P.; Camalier, C. E.; Stark, C.; Colburn, N. H.
  3. Molecular Cancer Therapeutics. 2004 3(2): 103-110.
  1. 22.   Sensitivity of renal cell carcinoma to aminoflavone: Role of CYP1A1
  2. Loaiza-Perez, A. I.; Kenney, S.; Boswell, J.; Hollingshead, M.; Hose, C.; Linehan, W. M.; Worrell, R.; Rubinstein, L.; Sausville, A.; Vistica, D. T.
  3. Journal of Urology. 2004 171(4): 1688-1697.
  1. 23.   Toxicity vs. antitumor activity of IL-12 and IL-18 cDNA injections in C57BL/6 mice
  2. Rodriguez-Galan, M. C.; Watanabe, M.; Young, H. A.
  3. Journal of Leukocyte Biology. 2004 (Suppl. S): 56-56.
  1. 24.   Chemical synthesis and biological properties of pyridine epothilones
  2. Nicolaou, K. C.; Scarpelli, R.; Bollbuck, B.; Werschkun, B.; Pereira, M. M. A.; Wartmann, M.; Altmann, K. H.; Zaharevitz, D.; Gussio, R.; Giannakakou, P.
  3. Chemistry & Biology. 2000 7(8): 593-599.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel